国際会議発表支援No

2023/8/1現在
発表詳細

支援区分

Takeo A, Makari Y, Endo S, Matsuyama J, Kawabata R, Sugimoto N, Taniguchi H, Nagai K,Tamura S, Nishijima J, Ueda S, Kimura Y,Tamura T, Kobayashi K, Kawakami H, Fujitani K, Sakai
D, Shimokawa T, Kurokawa Y Satoh T: Randomized, open-label, phase II study comparing five1

weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-

外部研究支援[統計]naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial,2018 Gastrical Cancers Symposum, American Society of Clinical Oncology, San Francisco, USA,2018
Kawada J, Imamura H, Matsuyama J, Fukui J, Nishikawa K, Kawase T, Shimokawa T, Kurokawa
Y, Satoh T, Furukawa H: A phase II study to examine the effectiveness of nutritional support
2with elemental diet for stage II/III gastric cancer patients receiving adjuvant chemotherapy with 外部研究支援[統計]S-1 (OGSG 1108), 2017 Gastrical Cancers Symposum, American Society of Clinical Oncology,
San Francisco, USA, 2017
Matsuyama J, Kurokawa Y, Nishikawa K, Kimura Y, Takeo A, Kawada J, Kawabata R, Makari Y,Tamura S, Doki Y, Sakai D, Shimokawa T, Satoh T: Randomized phase II study to compare

3docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions 外部研究支援[統計](HERBIS-3), 2017 Gastrical Cancers Symposum, American Society of Clinical Oncology, San
Francisco, USA, 2017.
Sugimoto N, Sakai D, Kawada J, Kawabata R, Nishikawa K, Kawase T, Oka Y, Shimizu T,Nishijima J, Hasegawa H, Endo S, Isozaki Y, Kimura Y, Matsuyama J, Kurokawa Y, Shimokawa T,

4Fujitani K, Satoh T.: A phase II trial of trastuzumab combined with irinotecan in patients with

外部研究支援[統計]advanced HER2-positive chemo-refractory gastric cancer: OGSG1203 (HERBIS-5), 2016
American Society of Clinical Oncology Annual Meeting, Cicago, USA, 2016
Nishikawa K, Sakai D, Kawada J, Kawabata R, Kawase T, Oka Y, Sugimoto B, Shimizu T,
Nishijima J, Hasegawa H, Endo S, Isozaki Y, Kimura Y, Matsuyama J, Kurokawa Y, Shimokawa T,5Fujitani K, Satoh T:A phase II trial of trastuzumab combined with irinotecan in patients with

外部研究支援[統計]advanced HER2-positive chemo-refractory gastric cancer：OGSG1203 (HERBIS-5), 2016
Gastrical Cancers Symposum, American Society of Clinical Oncology, San Francisco, USA, 2016
Yang HK, Kurokawa Y, Ryu HM, Cho H, Park SR, Masuzawa T, Lee HJ, Matsumoto S, Kwon OK,Honda H, Lee KH, Yamamoto K, Kong SH, Ishikawa T, Yook JH, Nabeshima K, Hahn S,6Shimokawa T, Kang YK and Nishida T：A multinational phase II clinical trial of neoadjuvant

外部研究支援[統計]imatinib for large gastrointestinal stromal tumor of the stomach, 2016 Gastrical Cancers
Symposum, American Society of Clinical Oncology, San Francisco, USA, 2016
Kawabata R, Sakai D, Kawada J, Nishikawa K, Kawase T, Oka Y, Sugimoto N, Shimizu T,
Nishijima J, Hasegawa H, Endo S, Isozaki Y, Kimura Y, Matsuyama J, Kurokawa Y, Shimokawa T,
7Fujitani and Sato T：A phase II trial of trastuzumab combined with irinotecan in patients with

外部研究支援[統計]advanced HER2-positive chemo-refractory gastric cancer：Osaka Gastrointestinal CancerChemotherapy Study Group OGSG1203 (HERBIS-5), ESMO Asia Congress, Singapore, 2015

国際会議発表支援和歌山県立医科大学附属病院

臨床研究センター

1 / 1 ページ